[144] Vir Biotechnology, Inc. SEC Filing

Rhea-AI Filing Summary

Vir Biotechnology, Inc. (VIR) – Form 144 filing overview

The filing discloses a proposed secondary sale of 66,000 common shares of Vir Biotechnology under Rule 144. The shares were originally acquired on 17 Jan 2017 as pre-IPO stock and are held in the name of an undisclosed insider (the form does not specify the individual or relationship to the issuer). Morgan Stanley Smith Barney LLC, Executive Financial Services, is listed as the broker for the transaction.

• Shares to be sold: 66,000
• Aggregate market value: US $332,640
• Planned sale date: 1 Jul 2025
• Total VIR shares outstanding: 138,238,003
• Percent of shares outstanding: ~0.05 % (66,000 ÷ 138,238,003)
• Exchange: NASDAQ

No sales by the filer have occurred within the prior three months, and the securities were not purchased with non-cash consideration according to the disclosure. The seller certifies awareness of no undisclosed material adverse information and acknowledges potential criminal liability for misstatements.

Given the modest size relative to VIR’s float and the absence of multiple tranches or recent insider selling, this notice is unlikely to have a material impact on the company’s capital structure or market dynamics. However, investors may monitor for additional filings that could signal a broader disposition program.

Positive

• Minimal dilution/float impact: 66,000 shares represent only ~0.05 % of the 138.2 million shares outstanding.
• Regulatory transparency: Advance notice under Rule 144 provides investors early visibility into possible insider transactions.

Negative

• Insider selling signal: Any sale by insiders can be perceived negatively, even if relatively small.
• Limited disclosure: The form omits the seller’s identity and relationship to the company, reducing clarity for investors.

Insights

Equity Research Analyst

TL;DR: Routine insider sale of 66k shares (~0.05 % of float); immaterial market impact expected.

The Form 144 indicates a prospective sale worth roughly US $333k, a fraction of Vir Biotechnology’s >138 million outstanding shares. Rule 144 notices are common for pre-IPO holders unlocking legacy shares. The filing contains no information on the seller’s role, which tempers interpretation of sentiment—an executive sale can differ from an early investor’s liquidity event. Absence of recent sales and the one-off nature suggest the transaction is housekeeping rather than a signal on fundamentals. I view the impact on share price and liquidity as negligible, though sustained selling would warrant closer scrutiny.

Corporate Governance Specialist

TL;DR: Governance neutral; disclosure meets Rule 144, but anonymity limits insight into insider intentions.

From a governance perspective, the filer complies with mandatory pre-sale disclosure, enhancing transparency. Yet, the lack of the individual’s identity or relationship to the issuer limits stakeholders’ ability to evaluate potential signaling effects. Since the form affirms no undisclosed adverse information and no 10b5-1 plan is noted, the transaction appears opportunistic rather than structured. Overall governance impact is neutral, but investors should watch future filings to see if key executives begin to reduce holdings materially.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	66000	332640.00	138238003	07/01/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/17/2017	Pre-IPO Shares	Issuer			66000	01/17/2017	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Vir Biotechnology (VIR) shares are being sold under this Form 144?

66,000 common shares are proposed for sale.

What is the dollar value of the proposed Vir Biotechnology share sale?

The aggregate market value is US $332,640 as stated in the filing.

When is the planned sale date for the VIR shares?

The approximate sale date disclosed is 1 July 2025.

How does the 66,000-share sale compare to Vir Biotechnology's total shares outstanding?

It represents about 0.05 % of the 138,238,003 shares outstanding.

Which broker is handling the VIR share sale disclosed in Form 144?

The broker is Morgan Stanley Smith Barney LLC, Executive Financial Services.

Were any VIR shares sold by this filer in the past three months?

No. The filing states "Nothing to Report" for past three-month sales.